Enrollment of the first patient in Europe represents continued progress in the global execution of ReVeRA-301 as we advance our pivotal Phase 3 program,” said David Bharucha, M.D., PhD, FACC, Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results